Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Phase 3
18–60
10 sites in AL, AZ, CA +3
What this study is about
This Phase 3 study is testing Frexalimab in people with multiple sclerosis.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
monoclonal antibody
Secondary: Medical device AEs, ADEs, SAEs, SADEs and device deficiencies throughout the study, Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation, AESIs, and potentially clinically significant abnormality(PCSA) in laboratory tests, and vital signs during the study period, Pharmacokinetic parameters: Cmax(part A), Pharmacokinetic parameters: Tmax(part A)
Neurology